Establishment of individualized therapy for pituitary tumors using organoid culture
| Project/Area Number |
17K19684
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Internal medicine of the bio-information integration and related fields
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Yamada Shozo
|
|---|
| Project Period (FY) |
2017-06-30 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2018: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2017: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Keywords | 下垂体腫瘍 / オルガノイド / 創薬 / ハイスループットスクリーニング |
|---|
| Outline of Final Research Achievements |
We aimed to establish pituitary tumor in vitro model using organoid culture methods. Upon these models, we can clarify the pathogenesis of the tumor and screen drugs based on the individualized approaches. Thus far, we have optimized the culture conditions using 67 pituitary tumors and cell lines. As a result, we have been able to cultivate more than 3 months with hormone secretion with proliferation for one month in the tumor. Interestingly, organoid culture methods abled the cell line to recover the responsiveness to the stimuli and drugs. We are further optimizing the protocol and aiming more useful organoid model.
|
| Academic Significance and Societal Importance of the Research Achievements |
脳腫瘍の中でも頻度が高い下垂体腫瘍には、薬剤抵抗性を示す腫瘍もしばしば見られる。このような薬剤抵抗性腫瘍に対する創薬は喫緊の課題であるが、適切なin vitroモデルが存在しないことが大きな障害になっている。これまでの研究の結果、初代培養系では２週間以上のホルモン分泌能の維持が困難であるところを、１ヶ月の増殖および３ヶ月のホルモン分泌能の維持が可能になった。また下垂体腫瘍細胞株の三次元培養系では形質の回復と薬剤反応性がみられ、ハイスループットスクリーニグによる腫瘍特性に合わせた創薬の基盤が確立された。これらの成果をさらに発展することにより難治性下垂体腫瘍の画期的な創薬を目指す。
|
Report
(3 results)
Research Products
(37 results)
-
-
-
-
-
[Journal Article] Multiple salivary cortisol measurements are a useful tool to optimize metyrapone treatment in patients with Cushing’s syndromes treatment; case presentations.2018
Author(s)
Yoshida K, Fukuoka H, Odake Y, Nakajima S, Tachibana M, Ito J, Hosokawa Y, Yamada T, Miura H, Suematsu N, Matsumoto R, Bando H, Suda K, Nishizawa H, Iguchi G, Ogawa W, Takahashi Y
-
Journal Title
Front Endocrinol
Volume: 8
Pages: 375-375
DOI
NAID
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] Factors correlated with serum insulin-like growth factor-I levels in health check-up subjects.2018
Author(s)
Matsumoto R, Koga M, Kasayama S, Fukuoka H, Iguchi G, Odake Y, Yoshida K, BandoH, Suda K, Nishizawa H, Takahashi M, Ogawa W, Takahashi Y
-
Journal Title
Growth Horm IGF Res.
Volume: in press
Pages: 55-60
DOI
Related Report
Peer Reviewed / Open Access
-
-
[Journal Article] A novel thymoma-associated autoimmune disease: Anti-PIT-1 antibody syndrome.2017
Author(s)
Bando H, Iguchi G, Okimura Y, Odake Y, Yoshida K, Matsumoto R, Suda K, Nishizawa H, Fukuoka H, Mokubo A, Tojo K, Maniwa Y, Ogawa W, Takahashi Y.
-
Journal Title
Sci Rep.
Volume: 20
Issue: 1
Pages: 43060-43067
DOI
NAID
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Book] 医学書院2018
Author(s)
高橋 裕
Total Pages
2160
Publisher
今日の治療指針
Related Report
-
-
-
-
-
-
-
